The companies on the Global 500 employ 70.2 million people, and their revenue represents more than one-third of the world’s GDP.

Fortune Global 500

With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

The 300 companies on this year’s list brought in over $12.5 trillion in revenue for the latest 12 months, with the median revenue figure at $24 billion.

America's Most Innovative Companies

AI is a major force shaping this year’s list—but it’s far from the only story.

World's Most Admired Companies

Companies that foster an environment that supports professional growth are more likely to thrive and successfully adopt digital innovation. Here are the 100 best places to work in Europe—and how they stay that way.

Johnson &amp; Johnson ranks 52 on this year’s Fortune 100 Best Companies to Work For – Europe list.

Fortune 100 Best Companies To Work For – Europe

This ranking evaluates how Fortune 500 companies are deploying AI, and how technology leaders value those investments relative to industry peers.

Fortune AIQ 50

The corporations on our annual list of the world's 500 largest companies combined to generate $41.7 trillion in revenue over the past year.

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

The 300 companies on this year’s list brought in over $12.6 trillion in revenue for the latest 12 months, with the median revenue figure at $22 billion.

Leaders in all industries rely more than ever on Big Tech—and appreciate the giants that deliver, at scale, without drama.

The corporations on our annual list posted aggregate revenues of $41 trillion for the second year in a row.

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The 200 companies on this list are transforming industries from the inside out.

The 26th edition of the list shows how much esteem Big Tech giants command among other business leaders.

WMA-2024-Johnson-and-Johnson

The 25th Fortune World’s Most Admired Companies list suggests that tech giants’ peers respect them as much as ever.

WMAC 2023-Johnson and Johnson

The corporations on our annual list of the world’s largest companies delivered a record $41 trillion in aggregate revenues.

The 300 companies on this list are transforming industries from the inside out.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

F500-2023-040-Johnson-and-Johnson

The health care company is best known for household items like baby shampoo and Tylenol, but pharmaceuticals and medical technology are its big revenue drivers, bringing in $52.5 billion and $27.4 billion respectively, compared to $14.9 billion in the consumer health segment. 
<ul> 
 	<li>Revenue inched up 1.2% to $94.9 billion in 2022, but profits fell 14.1% to $17.9 billion.</li> 
 	<li>The U.S. government phased out Johnson &amp; Johnson’s one-shot COVID vaccine, hurting the company’s pharmaceutical division.</li> 
 	<li>In April 2023, the company settled a decade-long legal dispute in which consumers accused J&amp;J’s iconic baby powder of causing cancer. The company agreed to pay $8.9 billion to tens of thousands of plaintiffs but has not admitted wrongdoing. Before the settlement is final, a court must accept a controversial bankruptcy filing by a subsidiary that Johnson &amp; Johnson created to shield its corporate assets from litigation. A court rejected an earlier bankruptcy filing aimed at reaching a settlement, which allowed thousands of related cases against J&amp;J to go ahead.</li> 
</ul>

Just as it dominates our economy, Big Tech now dominates Fortune’s annual ranking of corporate reputation.

WMAC-2022-17-Johnson and Johnson

Aggregate sales hit $37.8 trillion last year—an increase of 19%, the highest annual growth rate in the list’s history.

This year’s Fortune 500 marks the 68th running of the list.

F500 2022-Johnson and Johnson

J&amp;J is home to globally known household products such as Tylenol pain medication and Aveeno body lotion. But over the past year, its health care and pharmaceutical businesses made the most news. The company began distributing its Janssen single-dose COVID-19 vaccine in March 2021. Manufacturing problems and the vaccine’s lower efficacy compared with products from Pfizer-BioNTech and Moderna hindered its adoption, but as of May 2022 about 19 million doses had been administered in the U.S., and millions more internationally. In July 2021, J&amp;J agreed to pay up to $5 billion as part of a nationwide settlement agreement to fund state and local efforts to address the opioid crisis. (The company admitted no wrongdoing related to marketing of its pain medications.) And in November 2021 the company announced that it would essentially become a pharma pure play; by late 2023, J&amp;J will spin off its consumer products businesses as a separate company.

After a year in which humanity leaned more heavily than ever on tech giants, see which companies topped Fortune's ranking of corporate reputation.

WMAC 2021-15-Johnson & Johnson

Total revenue for the world’s biggest companies fell 4.8% to $31.7 trillion this year—the first decline in half a decade.

G500-2021-094-Johnson & Johnson

The 135-year-old global health care conglomerate sells everything from Band-Aids and artificial hips to surgical robots, cancer drugs, and one of America’s first three authorized COVID vaccines. The pandemic affected many of those businesses, and J&amp;J’s sales overall were relatively flat last year—notching up 0.6%. While the company’s pharmaceutical division performed well, results were mixed for the consumer segment: Sales of over-the-counter products like Tylenol surged, while baby care and women’s health revenues plummeted. Likewise, the company’s medical devices business recorded a sales decline of 11.6%, largely owing to people delaying procedures during the pandemic.

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-36-Johnson & Johnson

For an astounding 13th straight year, Apple claims the top spot in Fortune’s annual ranking of corporate reputation, based on a survey of almost 3,800 executives, directors, and analysts.

This year's Fortune Global 500 generated $33.3 trillion in revenues and $2.1 trillion in profits.

G500-2020-104-JJ

The sprawling 134-year-old health conglomerate eked out 0.6% sales growth in 2019 thanks to the strong performance of its pharmaceutical business, and particularly its immunology and oncology drugs. J&amp;J’s consumer business—with a portfolio that includes Neutrogena, Tylenol, and Listerine—was boosted by the acquisition of Zarbee’s, a purveyor of naturally based over-the-counter remedies. The company continued its push into the robotic surgery market in an effort to revive its struggling medical device business. J&amp;J is also mired in litigation surrounding its opioid and baby powder products. (In May, it announced it would stop selling talc-based baby powder.) While COVID-19 has dinged sales of some of its products—like contact lenses and artificial knees and hips—the company is one of the frontrunners in the race for a vaccine; J&amp;J has said it hopes to begin late-stage human trials by the end of September.

This year's Fortune 500 marks the 66th running of the list.

F500-2020-035-Johnson and Johnson

The sprawling 134-year-old health conglomerate eked out 0.6% sales growth in 2019 thanks to the strong performance of its pharmaceutical business, and particularly its immunology and oncology drugs. J&amp;J’s consumer business—with a portfolio that includes Neutrogena, Tylenol, and Listerine—was boosted by the acquisition of Zarbee’s, a purveyor of naturally based over-the-counter remedies. The company continued its push into the robotic surgery market in an effort to revive its struggling medical device business. J&amp;J is also mired in litigation surrounding its opioid and baby powder products. No surprise, the company has been impacted by COVID-19 in various ways; while its pharma division is racing to develop a vaccine, sales of products like artificial knees and hips are down due to the cancellation of elective surgeries during the pandemic.

Here are the World's Most Admired Companies for 2019 as ranked in their industries. See who made the list.

This year's Fortune Global 500 generated $27.7 trillion in revenues and $1.5 trillion in profits.

This year's Fortune 500 marks the 65th running of the list.

Here are the World's Most Admired Companies for 2018 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 64th running of the list.

Here’s our look at 57 companies that do well by doing good.

Change the World

Here are the World's Most Admired Companies for 2017 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 63rd running of the list.

Here’s our look at 50 companies that do well by doing good.

Here are the World's Most Admired Companies for 2016 as ranked in their industries. See who made the list.

This year's Fortune Global 500 generated $27.6 trillion in revenues and $1.5 trillion in profits.

This year's Fortune 500 marks the 62nd running of the list.

Business insiders have spoken: Asked which companies they most admire, more than 4,100 executives, directors, and analysts chose these top 50 All-Stars.

The world's 500 largest companies generated $31.2 trillion in revenues and $1.7 trillion in profits in 2014. Together, this year's Fortune Global 500 employ 65 million people worldwide and are represented by 36 countries.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Global business is back. After limping through a worldwide financial crisis and economic slowdown, the 500 largest companies ranked by revenues shattered all sorts of performance records in 2013: They racked up combined revenues of $31.1 trillion, up 2.5% from 2012, and profits soared 27% to nearly $2 trillion. China’s 95 companies (up from 89 last year) posted $5.8 trillion in revenues. The U.S. has four fewer companies on the list than last year but remains (for now) the country leader, with 128 corporations on the list—including No. 1 Wal-Mart Stores—reporting $8.6 trillion in revenues. 

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Best Companies To Work For Europe

Sector

CEO/Top executive

Group headquarters

HQ location

GPTW national list

Woman CEO

Number of Years on List

Industry

Current All-Star Rank

Previous All-Star Rank

Industry Rank

Previous Industry Rank

Overall Score

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Strongest Dimension

Years on list

Previous rank

State

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Johnson &amp; Johnson, founded in 1886, is among the world’s largest and most influential health care companies. It is involved in the research, development, manufacture, and distribution of innovative medicines and medical technologies. The company’s innovative medicine business operates in areas including oncology, immunology, neuroscience, and cardiopulmonary treatment. In medtech, the company is focused on developing and delivering cardiovascular, orthopedics, surgery, and vision solutions.

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Johnson & Johnson (JNJ): Company Profile, Stock Price, News, Rankings

legacy

Johnson & Johnson

johnson & johnson

Good morning and welcome to Johnson & Johnson.

Johnson's third quarter 2025 earnings conference call.

All participants will be in the listen-only mode until the question and answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time.

If you experience technical difficulties during the conference, you may press Star 0 to reach the operator.

Hello everyone, this is Darren Snellgrove, Vice President of Investor Relations for Johnson & Johnson. Welcome to our 2025 third quarter review of business results and updated financial outlook. First, a few logistics. As a reminder, today's presentation and associated schedules are available on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. Please note that this presentation contains forward-looking statements regarding, among other things, the Company's future operating and financial performance, market position and business strategy. You are cautioned not to rely on these forward-looking statements, which are based on the current expectations of future events using the information available as of the date of this recording and are subject to certain risks and uncertainties that may cause the Company's actual results to differ materially from those projected.

A description of these risks, uncertainties and other factors can be found in our SEC filings, including our 2024 Form 10-K, which is available at investor.jnj.com and on the SEC's website. Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships. Moving to today's agenda, Joaquin Duato, our Chairman and CEO, will discuss our business performance and growth drivers. I will then review the third quarter sales and P&L results. Joe Wolk, our CFO, will then close by sharing an overview of our cash position and capital allocation priorities, followed by additional details on our intended separation of the orthopedics business. He will also provide an update on 2025 guidance, key milestones and qualitative considerations for 2026.

Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine, John Reed, Executive Vice President, Innovative Medicine Research and Development, and Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, will be joining us for Q&A. To ensure we provide enough time to address your questions, we anticipate the webcast will last approximately 60 minutes. With that, I will now turn the call over to Joaquin.

Thank you, Darren, and hello everyone. We are looking forward to sharing our very strong third quarter results with you. They are a clear sign Johnson & Johnson is in a powerful new era of growth. The success of our portfolio and pipeline is proof that our relentless focus on innovation is doing more than fueling progress, it is accelerating it. In the third quarter, we delivered operational sales growth of 5.4% across our business. In Innovative Medicine, we reported 5.3% operational sales growth and a second consecutive quarter of sales of more than $15 billion. Some were not convinced we could grow through the loss of exclusivity of Stelara, but we were confident and we have now unequivocally answered that question. How did we accomplish that when other companies have failed?

In Q3, we did it by delivering double-digit growth across 11 brands including Darzalex, Carvykti, Talvey, Tecvayli, Erleada, Rybrevant, Pluvicto, Caplyta, Spravato, Symponi, Remicade, and remarkable growth of 40% in Tremfya. In MedTech, operational sales growth was even stronger, accelerating to 5.6% with improvements across all businesses. As you have seen from this morning's news, we have announced the planned separation of our orthopedics business. This decision further sharpens our focus as a healthcare innovation leader and accelerates the shift of our MedTech portfolio to areas of greatest unmet need and higher growth, which includes cardiovascular and robotic surgery. I will touch more on this later, but one thing is clear, Johnson & Johnson's momentum is strong and our achievements are multiplying. I will now focus on the progress we are making across our six priority areas: oncology, immunology, neuroscience, cardiovascular surgery, and vision.

These are areas where we have deep expertise and clear leadership positions. First, oncology, where Q3 operational sales grew nearly 20%. You have heard me say before that we are much more than a one-shot company and our expertise in blood cancers and solid tumors in our oncology portfolio is a great example. Take multiple myeloma, where our competitiveness is unrivaled. No other company has the expertise or success in multiple myeloma that we do. We have treatments in every line of therapy and Darzalex is the gold standard with more than 50% market share across all lines of therapy. Q3 operational sales of Darzalex grew by 20% and its potential continues to build with the approval this quarter in Europe as a treatment for high risk smoldering multiple myeloma as well as promising new studies of Darzalex Faspro in combination with teclistamab.

I also want to say a word about Carvykti, our CAR-T treatment for multiple myeloma. We have now treated more than 8,500 patients globally, making Carvykti the most successful CAR-T launch ever. With operational sales growing by more than 80% this quarter, we are increasingly confident in Carvykti's $5 billion peak year sales potential. Turning to solid tumors, we were thrilled to receive FDA approval for our bladder cancer treatment Inlexa last month. Inlexa highlights what is unique about Johnson & Johnson. Building on our unmatched capabilities in both Innovative Medicine and MedTech, it is the first and only drug releasing system to provide sustained local delivery of a cancer treatment directly into the bladder. It is transformative for patients and it is transformative for doctors.

It will also contribute significantly to future growth with a targeted release platform projected to be another blockbuster treatment with at least $5 billion in annual peak year sales. Sourced through an early stage deal, Inlexa is also an example of our outstanding business development model. In fact, in the last 18 months alone we have completed more than 60 deals of this kind and in lung cancer we recently published results in the New England Journal of Medicine for riviprant plus lazertinib showing a statistically significant reduction in the risk of death compared to osimertinib. We are now seeing the potential for patients to live significantly longer than anyone thought possible. The combination of riviprant plus lazertinib is another of our $5 billion peak year sales assets. Next I want to talk about Immunology, where we have been leaders for 25 years.

From Remicade to Simponi and Stelara to Tremfya, some of our biggest blockbusters have come from our immunology portfolio. We have long talked about Tremfya as the next big innovation to follow the success of Stelara. Based on this quarter's performance, it looks like it could be both bigger and better. Having delivered operational sales growth of 40% driven by new indications in inflammatory bowel disease, Tremfya is the only IL-23 inhibitor to offer a fully subcutaneous regimen across ulcerative colitis and Crohn's disease. Even prior to the launch of our subcutaneous formulation, Tremfya was capturing approximately half of all new patient starts for IL-23 ulcerative colitis treatments in the U.S., which we achieved within one year from launch.

We are confident Tremfya will become a more than $10 billion asset, and in typical J&J fashion, we are deep in development of our next immunology innovation, icatrekibart, initially for moderate to severe plaque psoriasis. Historically, the most effective immunology treatments have been injectables. As the first oral peptide to selectively block the IL-23 receptor, icatrekibart has the potential to revolutionize the treatment of plaque psoriasis with a once-a-day pill. We submitted icatrekibart for plaque psoriasis to the FDA in July. This is just the beginning, as we have already presented data from our phase 2 trials in ulcerative colitis. Let's now turn to neuroscience. With Spravato operational sales growing an impressive 61% in Q3, Spravato remains the only approved standalone therapy for treatment-resistant depression, a major depressive disorder with suicidal ideation.

Through Q3, we have now treated more than 180,000 patients, and I could not be prouder of the impact this team is having. Our leadership in neuropsychiatry was also strengthened by this year's acquisition of Intra-Cellular Therapies. With FDA approval for Caplyta in major depressive disorder anticipated soon, Caplyta is already FDA approved for the treatment of schizophrenia as well as depressive episodes associated with bipolar disorder 1 and 2. We project Caplyta to reach $5 billion annually. Now let's turn to MedTech, starting with our cardiovascular portfolio. In Q3, cardiovascular operational sales increased by approximately 12% as we fortify our leadership in the fastest growing cardiovascular intervention segments. With operational sales growth of over 20%, Shockwave's unique intravascular lithotripsy technology is helping treat more atherosclerotic cardiovascular patients than ever before.

In fact, in the last quarter, Shockwave supported their 1 millionth patient, and with the recent European approval of the Javelin peripheral intravascular lithotripsy catheter, we expect strong momentum moving forward. We anticipate Shockwave becoming our 13th billion dollar MedTech platform by year end. In electrophysiology, we are industry leaders, and with the strength of our mapping technology that continues in Q3, we again delivered close to 10% operational sales growth, and our position was further strengthened with real world data showing Varipulse achieved 99.7% acute effectiveness in nearly 800 patients with strong safety and no incidence of stroke. Our Abiomed business also continues to perform strongly with more than 15% operational sales growth in the quarter.

Our success reflects the impact that our Impella CP heart pump is having on the lives of patients, which you could see in the long term survival data that was published in the New England Journal of Medicine this quarter. In the 10-year DANGER Shock study, routine use of Impella CP in patients who have had a heart attack with cardiogenic shock reduced mortality by 16.3% compared to the standard of care, with patients gaining an average of 600 additional days alive. It is a perfect example of what we mean when we say Johnson & Johnson is delivering groundbreaking innovation in surgery. We are making progress on multiple fronts. Our surgical technologies are used in most operating rooms globally, and in Q3 we delivered more than 9% growth in biosurgery and almost 7% in wound closure, driven by accelerating adoption of our latest innovations.

We also continue to make positive progress with OTAVA as we anticipate FDA de novo submission in early 2026. Now to Vision, where we grew more than 6% last quarter. Our TECNIS intraocular lenses are the fastest growing in the markets. What we have launched is fueling our 13.8% operational sales growth in surgical vision, and after launching the world's first multifocal contact lens for people with astigmatism in the U.S. last quarter, we brought this latest member of the ACUVUE OASYS MAX 1-Day family to Europe and Korea in Q3, further strengthening our momentum. Finally, to this morning's Orthopaedics news. As you know, the healthcare industry continues to evolve rapidly, and we are constantly evaluating our overall business and portfolio to ensure Johnson & Johnson remains best positioned to truly lead where healthcare is going.

We continue to invest at industry leading levels in our pipeline and portfolio while making disciplined decisions to exit businesses that we believe will be better able to thrive outside of Johnson & Johnson. For our orthopedics business, the planned separation creates new opportunities. Operating as DePuy Synthes and led by Namal Nawana, it would be the largest, most comprehensive orthopedics company with leading market share positions across major categories and addressing a more than $50 billion and growing market opportunity. We expect DePuy Synthes to benefit from a more focused business model with greater flexibility to extend its market leadership, invest in its commercial capabilities, and capitalize on profitable growth opportunities.

Following the completion of the planned separation, Johnson & Johnson will retain a leadership position in our six core growth areas across innovative medicine and MedTech for oncology, immunology, neuroscience, cardiovascular surgery, and vision, and be able to place even greater focus in our investment towards higher growth areas where we can meaningfully extend and improve lives. We are positioning each business to win and deliver for our stakeholders as we move forward in the separation process. We will provide additional information as appropriate, and Joe will share more details shortly. As I said at the start of the call, we are in a new era of accelerated growth at Johnson & Johnson. This is more than just another strong quarter. It is proof that our momentum is building and that our impact is accelerating. Thank you very much, and I will now turn the call back over to Darren.

Thank you, Joaquin. Moving to our financial results, unless otherwise stated, the percentages quoted represent operational results and therefore exclude the impact of currency translation. Starting with Q3 2025 sales results, worldwide sales were $24 billion for the quarter. Sales increased 5.4% despite an approximate 640 basis point headwind from Stelara. Growth in the U.S. was 6.2% and 4.4% outside of the U.S. Acquisitions and divestitures had a net positive impact on worldwide growth of 100 basis points, primarily driven by the Intra-Cellular acquisition. Turning now to earnings for the quarter, net earnings were $5.2 billion with diluted earnings per share of $2.12 versus diluted earnings per share of $1.11 a year ago. Adjusted net earnings for the quarter were $6.8 billion with adjusted diluted earnings per share of $2.00, both representing an increase of 15.7% compared to the third quarter of 2024.

As a reminder, results in the third quarter of 2024 were impacted by the acquired IPR&D expense of $1.25 billion associated with the NM26 bispecific antibody. I will now comment on business sales performance in the quarter, focusing on the six key areas where meaningful innovation is driving our performance and fueling long-term growth, beginning with Innovative Medicine where our results demonstrate the depth of our expertise across oncology, immunology, and neuroscience. Worldwide sales of $15.6 billion increased 5.3% despite an approximate 1,070 basis point headwind from Stelara, illustrating the continued strength of our key brands and new launches. Growth in the U.S. was 6% and 4.3% outside of the U.S. Acquisitions and divestitures had a net positive impact of 160 basis points on worldwide growth due to the Intra-Cellular acquisition.

In oncology, starting with multiple myeloma, Darzalex growth was 19.9%, primarily driven by continued strong share gains of approximately 5.7 points across all lines of therapy, with nearly 9 points in the frontline setting as well as market growth. Carvykti achieved sales of $524 million with growth of 81.4% driven by share gains and site expansion. This reflects continued strong sequential growth of 18.5% as our expansion outside the U.S. progresses. Tecvayli and Talvey growth was 29.9% and 59.1% respectively, bolstered by continued expansion into the community setting. In prostate cancer, Erleada delivered strong growth of 15.3% due to market growth and continued share gains, partially offset by the impact of Part D redesign. In lung cancer, Rivipansel plus Lasclus delivered sales of $198 million and growth over 100% driven by continued strong launch uptake. We continue to see share gains in both first and second lines of therapy.

Within Immunology, Tremfya delivered very strong growth of 40.1%. We continue to see share gains across all indications with particularly robust momentum from our IBD launch. Stelara declined by 42% driven by the impact of biosimilar competition and Part D redesign, which is in line with our expectations. In neuroscience, Spravato grew an impressive 60.8% driven by continued strong demand from physicians and patients. Caplyta, which was acquired in Q2 as part of the Intra-Cellular Therapies acquisition, delivered sales of $240 million and reflects healthy sequential growth of 13.4%. Now moving to MedTech, worldwide sales of $8.4 billion increased 5.6% with growth of 6.6% in the U.S. and 4.5% outside the U.S. driven by strong performance in our three focus areas, cardiovascular surgery and vision. Acquisitions and divestitures had a net negative impact of 10 basis points on worldwide growth.

In cardiovascular, electrophysiology delivered growth of 9.7% versus prior year driven by procedure growth, commercial execution, Varipulse and other new products and strength in competitive mapping. Abiomed delivered growth of 15.6% with continued strong adoption of Impella technology and Shockwave increased 20.9% driven by double-digit growth globally in both coronary and peripheral. Surgery grew 3.3% despite divestitures negatively impacting results by approximately 50 basis points. Performance was primarily driven by technology penetration in wound closure, the strength of the portfolio and commercial execution in biosurgery as well as a one-time reserve adjustment in the quarter. Growth was partially offset by competitive pressures in energy and the negative impact of China VBP. Across the portfolio in vision, contact lenses and other products grew 3.5% driven by market growth, strong performance in the ACUVUE OASYS 1-Day family of contact lenses.

This includes the recent launches of OASYS MAX 1-Day multifocal for astigmatism and MAX 1-Day for astigmatism as well as continued strategic price actions. Surgical Vision had another strong quarter with growth of 13.8% driven by new product. Product innovations such as TECNIS PureSee, Odyssey and Eyhance, robust demand and strong commercial execution. These results further solidify our leadership positions in vision. As Joaquin noted, we have today announced our intent to separate the orthopaedic business. Orthopaedic growth this quarter is gaining momentum and increased to 2.4%. Importantly, hips and knees returned to growth this quarter, delivering 5.1% and 5.6% growth respectively. Now turning to our consolidated statement of earnings for the third quarter of 2025, I'd like to highlight a few noteworthy items that have changed compared to the same quarter a year ago.

Cost of products sold leveraged by 60 basis points, driven by a reduction in amortization expense and favorable currency in the Innovative Medicine business, as well as the non-recurring fair value inventory step up related to Shockwave in 2024. This was partially offset by unfavorable product mix in Innovative Medicine along with MedTech macroeconomic factors. Selling, marketing, and administrative expenses deleveraged by 40 basis points, driven by increased investment in the recent Intra-Cellular acquisition for Caplyta and promotional spend across the Innovative Medicine business, partially offset by expense leveraging in MedTech. Research and development expenses leveraged by 670 basis points, primarily driven by the expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody recorded in 2024. We continued our strong investment in research and development with $3.7 billion, approximately 15% of sales in Q3.

Interest income and expense was a net expense of $18 million as compared to $99 million of income in the third quarter of 2024, primarily driven by a higher average debt balance and a lower average cash balance. Other income and expense was net income of $0.5 billion compared to an expense of $1.8 billion in the prior year, primarily driven by a TALC litigation charge in 2024 and higher gains on the sales of securities in 2025, partially offset by the monetization of royalty rights recorded in 2024. Regarding taxes in the quarter, our effective tax rate was 31.2% compared to 19.3% in the same period last year. The increase is primarily driven by the one-time $1 billion remeasurement of deferred tax balances, which are required to reflect the changes in statutory tax rates associated with the enactment of the One Big Beautiful Bill Act in the third quarter.

More information can be found in the company's Form 10-Q. Lastly, I'll direct your attention to the box section of the slide where we have also provided the company's income before tax, net earnings, and earnings per share adjusted to exclude the impact of intangible amortization expense and special items. Now let's look at adjusted income before tax by segment for the quarter. Innovative Medicine margin improved from 37.9% to 44.3% primarily driven by the one-time expense of $1.25 billion to secure the global rights of the NM26 bispecific antibody recorded in 2024, partially offset by increased investment in commercial spend in 2025 and the non-recurring monetization of royalty rights in 2024. MedTech margin declined from 24.1% to 21% driven by macroeconomic factors in cost of products sold, partially offset by expense leveraging in SMA.

This concludes the sales and earnings portion of the call, and I will now turn the call over to Joe. Thanks.

Hello everyone and thank you for joining us today. In the third quarter, we sustained momentum across our in-market portfolio, delivering upon the heightened financial expectations we guided to last quarter. In Innovative Medicine, we continue to grow through the STELARA loss of exclusivity as.

The progression of our pipeline, evidenced by significant regulatory milestones, adds further depth to our three focus areas of oncology, immunology, and neuroscience. We are well positioned for the balance of the decade. In MedTech, we improved adjusted operational sales across key areas of the business. As Joaquin mentioned, we are sharpening our focus on high-growth, high-margin markets where we can improve patient outcomes, as this morning's announcement regarding the DePuy Synthes business indicates. In a moment, I will build upon Joaquin's comments regarding that announcement. The foundation we have set, combined with the progression of our pipeline, strongly positions the company for accelerated growth. It also reinforces our conviction to deliver on the upper end of our long-term growth targets. Let me provide a brief update on the Daubert motions pending in the talc litigation.

As you are aware, this is the judicial process by which the court will reexamine the junk science that the mass tort plaintiff's bar concocts to fuel baseless claims against Johnson & Johnson as well as many American businesses. We look forward to and expect to secure favorable rulings on the Daubert motions, which should be rendered by the first quarter of 2026. Now turning to cash and capital allocation, we generated $14 billion in free cash flow through the first nine months of the year. We ended the third quarter with approximately $19 billion in cash and marketable securities and $46 billion of debt for a net debt position of $27 billion versus the $32 billion of net debt reported in the second quarter. We continue to utilize our free cash flow generation and strong balance sheet to invest in innovation and return capital directly to shareholders.

We are often asked about our appetite for acquisitions to meet financial targets. I can be very clear on this. We rely on a thoughtful, long-term approach to growing through any loss of exclusivity and won't carelessly deploy capital on transactions out of desperation. Our current portfolio and pipeline have momentum, and with the Stelara loss of exclusivity increasingly in the rearview mirror, we do not need to rely on large transactions to drive our growth. We intend to remain disciplined, opportunistically pursuing strategic, high-value opportunities that utilize our expertise and capabilities that deliver an appropriate return for the risk that we bear on behalf of shareholders. Regarding the planned separation of our orthopedics business, as Joaquin noted, the separation is expected to enhance the strategic and operational focus of each company and drive value for our shareholders and other stakeholders.

Given that we are early in the process, there are limited details available, but we are committed to providing you with information on a timely basis. While we will of course communicate material developments, we don't expect to have anything newsworthy to convey until mid next year. What can we say at this moment? First, the separation will further strengthen our overall MedTech business and increase Johnson & Johnson's top line growth and margins. To give that some directional context, if we just look at normalized year to date 2025 results, MedTech's top line revenue growth and operating margin would both improve by at least 75 basis points. Next, we are targeting completion of the separation within 18 to 24 months, subject to the satisfaction of certain conditions given it is the most resource intensive and likely longest duration.

We are prioritizing and have begun the separation assuming a spinoff with the intention for that to qualify as a tax free separation for U.S. Federal income tax purposes. However, we will consider other avenues that optimize shareholder value. We do not expect any change to the Johnson & Johnson dividend and are mindful of any impact from stranded costs that are typically present in these types of transactions. Finally, following the separation, we would expect DePuy Synthes to have a strong capital structure that would allow the orthopedics business to build on its long history of innovation and extend leadership positions through enhanced organic investment and strategic growth. Accretive M&A as we pursue this separation, the orthopedics unit will operate in alignment with the business current strategy, continuing to make investments in growth, margin improvement and innovation.

Turning now to full year guidance for 2025, we are increasing operational sales guidance for the full year by approximately $300 million, resulting in operational sales growth for the full year in the range of 4.8% to 5.3%. With a midpoint of $93.2 billion or 5.1% excluding the impact from acquisitions and divestitures. Our adjusted operational sales growth is now expected to be in the range of 4.0% compared to 2024. As a reminder, we started the year guiding to a midpoint for 2.5% for adjusted operational sales. As you know, we don't speculate on future currency movements and last quarter we utilized the Euro spot rate relative to the U.S. dollar of 1.17. The U.S. dollar has stayed relatively flat to the Euro spot rate and as a result we now expect reported sales growth between 5.4% to 5.9% with a midpoint of $90 billion or 5.7%.

Turning to other notable items on the P&L, we are reiterating our operating margin guide of an approximate 300 basis point improvement for the full year. Assuming what we know today as it relates to tariffs for net interest expense, we are now projecting between $0 and $50 million, an improvement from the previous guidance primarily driven by higher cash balances. We are expecting a higher effective tax rate to be in the range of 17.5% to 18% for the full year, with the increase largely due to the recently enacted One Big Beautiful Bill Act. We feel strongly that U.S. tax policy has enabled Johnson & Johnson to increase our manufacturing footprint in the U.S. We have more manufacturing facilities in the United States than in any other country and we remain committed to investing $55 billion in U.S.-based innovation and manufacturing over the next four years.

In March we broke ground at our Wilson, North Carolina facility and in August we announced a $2 billion commitment to further increase our presence in North Carolina with a more than 160,000 square foot dedicated manufacturing facility at Fujifilm's new biopharmaceutical manufacturing site in Holly Springs. Our overall U.S. investment plans also include three additional new advanced manufacturing facilities as well as the expansion of several existing sites. Turning to earnings per share, you may recall we started the year guiding to adjusted EPS of $10.60. Today we stand much higher even after including dilution of $0.25 from the Intra-Cellular acquisition. Today we are reaffirming our elevated July earnings per share outlook, which also absorbs a higher annual effective tax rate and fourth quarter investments that will further position the business for success.

As such, our expected adjusted earnings per share guidance remains $10.85 or 8.7% at the midpoint, with a range of $10.80 to $10.90. Our adjusted operational earnings per share guidance is $10.68 or 7% at the midpoint. Looking beyond our financial commitments for the year, we are on track to add to the already impressive number of milestones that we achieved across our pipeline in 2025. In Innovative Medicine, we anticipate U.S. FDA approval for subcutaneous Riviprant for non-small cell lung cancer as well as for Caplyta, an adjunctive major depressive disorder. We recently filed for a label expansion on Tremfya in psoriatic arthritis and plan to present data for Riviprant in head and neck cancer at ESMO in the coming week. In MedTech, we continue to make progress with our clinical trial for our OTAVA robotic surgical system in our cardiovascular portfolio.

We are planning regulatory submissions for the Dual Energy ThermoCool SmartTouch SF catheter for cardiac arrhythmia in the U.S. and envision we will continue to roll out ACUVUE OASYS MAX for astigmatism. As we are close to year end and with the strong caveat that we are still finalizing plans for next year and macro factors can change quickly, let me provide some preliminary thoughts to inform your modeling for 2026. For Innovative Medicine, we remain very confident in our ability to deliver accelerated growth despite Stelara loss of exclusivity. This will be driven by our in-market brands and continued progress from our recently launched products including Tremfya in inflammatory bowel disease, Riviprant plus LAS clues in non-small cell lung cancer, and Inlexa in bladder cancer. We currently anticipate a 2026 approval for icatrekibart in psoriasis.

In MedTech, we continue to expect accelerated growth off this year's levels driven by focus on higher growth markets as well as the continued adoption of newer products across all MedTech platforms. We also anticipate the launch of Shockwave C2+ AERO Coronary IVL Catheter, the TECNIS PureSee intraocular lens in the U.S. as well as regulatory submission for the OTAVA robotic surgical. Again, while early, I like the way 2026 is shaping up. In fact, based on my last look at your 2026 models, it appears the current revenue consensus of 4.6% growth in your models for 2026 is lower than we project, which we believe in total will exceed 5%. Similarly, with the expectation that adjusted earnings per share is commensurate with sales growth, there appears to be some upside to the current adjusted earnings per share consensus of $11.39, perhaps as much as $0.05.

This commentary considers investments we will be making behind many of the new product launches I just highlighted, but you can also expect some margin improvement. It also reflects our understanding of the present legislative landscape, tariffs, foreign exchange rates, and procedural volumes. We look forward to sharing further details regarding our official guide for 2026 during our Q4 earnings call in January. In summary, the strength of our business model, with a focus on where we can have the greatest impact for patients, will enable Johnson & Johnson to deliver against our strategic objectives and financial commitments. We are as confident as we have been in recent memory about the future. I'd like to end my remarks by thanking our colleagues around the world for their continued hard work and steadfast dedication that serve our patients and who make these financial results possible and sustainable.

With that, we are happy to take your questions. Kevin, will you please open the call for Q&A?

Ladies and gentlemen, if you'd like to ask a question at this time, please.

Press Star then one on your telephone keypad. If you'd like to withdraw your question, please press Star then two.

To one question only. Our first question is coming from Alex Hammond from Wolfe Research. Your line is now.

Good morning and thanks for taking the question on the orthopedic spin out. I'd be interested to understand the why now, and also could we expect similar separations for other divisions in the future? As a quick follow up, how should we think about the long term guidance in light of the separation? Could we expect Johnson & Johnson to revisit these forecasts in the near term?

Thank you, Alex. Let me take the first question. Why now? Why the orthopedic separation? It's been a hallmark of Johnson & Johnson to be a good steward of our capital and to make decisions in our portfolio to prioritize where we think breakthrough innovation can come through. That's exactly what we are doing. We're moving Johnson & Johnson into high growth markets with significant medical need, and at the same time, we have the foresight to recognize when a standalone company could be better and could be in a better position to drive growth, innovation, and better margins. That's exactly what we are doing with our orthopedic separation.

We are fueling the innovation within Johnson & Johnson, focus on our six priority areas, continue to invest as we are doing in cardiovascular with the acquisitions of Abiomed, Shockwave, and also in pharmaceuticals with the acquisition of Intra-Cellular, and creating a standalone company that is going to be a champion within the context of the orthopedics sector. Orthopedics is a growing market, $50 billion market. It's fueled by the aging of the population, and we have commanding market shares in the most important segments of the orthopedics business. The company is going to be called DePuy Synthes. It's going to be led by Namal Nawana, who is an industry veteran. I have no doubt that they are going to be better positioned to succeed, to drive innovation, to drive growth, and to become what they are, the largest orthopedics company in the world.

Overall, this is a clear move to be able to manage our portfolio, to position Johnson & Johnson to be able to deliver breakthrough innovation, and the results that you are seeing so far with a very, very strong quarter. I want to underline this is not only a very strong quarter, it's also an indication, a signal that Johnson & Johnson is in an accelerated cycle of growth, which we expect is going to last the balance of the decade. Moving in the right direction. I'm sure investors are going to be happy to see that Johnson & Johnson is an active portfolio manager.

Yes, Alex, maybe just to build on Joaquin's comments. Thanks for the question. There were two other parts that I thought I heard from you. This is not a precursor to anything else. We look at what we have now in the clarity of our portfolio. Three strong strongholds in innovative medicine serving unmet needs with transformational innovation that elevates the standard of care in oncology, neuroscience, and immunology. Likewise, now in MedTech where we have market-leading positions, cutting-edge technology that is improving care for patients in surgery, eye health, and cardiovascular. We are going to be real pleased with the portfolio and we think Orthopaedics is set up for success going forward based on their profile and their ability to compete against other singularly focused orthopedics companies with respect to guidance revisions. As we mentioned in the scripted commentary, this will take 18 to 24 months.

Anything we say about 2026 will likely include the orthopedics business in our outlooks. We would expect maybe some material developments middle of next year, but we commit to keeping this audience particularly advised on a timely basis should anything material unfold.

Thank you. Next question today is coming from Daniela Antalpi from UBS. Your line is now live.

Hey, good afternoon, guys. Thanks so much for taking the question. Just a question on Joe, your commentary around potential margins post the Ortho Spin 75 bps. I don't want to get too greedy, but that feels a little light to me. Just curious about why, you know, given the mix of the business, it's high growth cardiovascular surgery, which I think should be relatively high margin, and vision feels like maybe it could be a little bit more than that. Just want to make sure I understand the puts and takes to that 75 bps number. Appreciating that's just, you know, a very early target.

Yeah, thanks, Danielle. That's an insightful question and I think it really depends on the time period by which you're measuring. If we were just to take 2025, you're absolutely right, it would be probably closer to 100 bps both on top and bottom or margin improvement. What I would say is we looked out a couple years given this will take a couple years to go through the process. As Abiomed, Shockwave, and the other businesses have higher growth profiles, margin improvements, initiatives that are already underway under Tim's leadership, it will have a more muted impact as it goes forward. I think on today's math, you're probably closer to being right. It's okay. I don't consider it greedy. Tim might, but I don't.

I think as you look out a little bit further with some of the stronger profile businesses, from a financial perspective, it'll have more of a muted impact.

Comments, as I'm sure there'll be a lot of questions on this topic, and we'd like to try and get them out of the way so we can.

I wanted to highlight why this makes sense for Johnson & Johnson MedTech, as you've heard from Joaquin.

To continuous portfolio optimization and value creation.

As you know, we've been on a journey over the last several years to really aggressively move our portfolio.

Into higher growth markets. Adding attractive assets such as Abiomed and Shockwave in high growth markets like cardiovascular are good examples of the bold.

Moves we already made in. Now this decision to separate Ortho is.

One that participates, as you know, in lower growth markets.

This is all about shrinking to grow faster for MedTech. Last time I looked.

You're not rewarding size, but really rather.

That is the path that we're on. As you already have heard, we expect the separation would increase our top line growth and margins following the completion. This allows us in MedTech really to focus on the businesses that will remain, which is our priorities of cardiovascular surgery and vision.

Thank you. I want to reiterate, as I told you day one when I became CEO, that I am fully focused, determined to make our MedTech sector the best-in-class MedTech group in the industry. That is a total priority for me, is a priority for Johnson & Johnson, and we are fully committed to deliver on that. We are on track to become the best MedTech sector in the industry.

Chris Schott from J.P. Morgan. Your line is now live.

Maybe just a question for Joaquin. There seems like there might be a framework for MFM agreements with the administration that's emerging across the space, focused on.

Can you just talk about how you're thinking about MFN tariffs, et cetera, and Johnson & Johnson's approach to some of these kind.

Of policy dynamics that are floating around out there. Thanks so much.

Thank you for the question. We've been talking with this administration with an open dialogue since day one, even before day one. We are always looking, as we have done as Johnson & Johnson, for common ground to build in the administration priorities that are similar to ours. Priorities like making sure that American patients have access to innovation in an affordable and timely way. Priorities like making sure that foreign entities do not free ride on American innovation. Making sure that we are able to maintain the overall leadership that this country has in life sciences. Finally, making sure that we continue to invest in manufacturing in this country to build good middle class jobs. We are delivering on that. We announced our plan to invest $55 billion in the U.S.

in the next four years, which essentially is going to make it so that all our advanced medicines that are used in the U.S. are going to be manufactured in the U.S. As far as the discussions, those are ongoing, I don't have anything to share today, but I am optimistic that we are going to land in a place which is going to create common ground between the administration and ourselves. Thank you.

Our next question today is coming from Larry Biegelsen from Wells Fargo.

Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript

Company Participants